Drug intelligence / Profile preview

cholecalciferol + memantine

Development stage: Unknown
Lead developer: Centre Hospitalier Universitaire d'Angers
Modality: Small Molecules
Administration: Oral

Overview

A combination of vitamin D3 (cholecalciferol) and memantine that has shown synergistic neuroprotective effects in Alzheimer's disease. The combination appears to prevent axon degeneration induced by amyloid-beta and glutamate toxicity more effectively than either component alone. Clinical studies have demonstrated improved cognitive outcomes in Alzheimer's patients receiving this combination compared to monotherapy with either agent.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on cholecalciferol + memantine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cholecalciferol + memantine.

Explore the full profile